| P2093 | author name string | Michele I Morris | |
| | Daniel H Kett | |
| | Andrew A Quartin | |
| | Marcela A Ferrada | |
| P2860 | cites work | Acute Physiology and Chronic Health Evaluation (APACHE) IV: Hospital mortality assessment for today’s critically ill patients* | Q63112282 |
| | Economic analysis of fluconazole versus amphotericin B for the treatment of candidemia in non-neutropenic patients | Q77165677 |
| | National epidemiology of mycoses survey (NEMIS): variations in rates of bloodstream infections due to Candida species in seven surgical intensive care units and six neonatal intensive care units | Q78221560 |
| | Determinants of mortality in patients with severe sepsis | Q80977050 |
| | Selection bias in Andes et al | Q84404217 |
| | Quality and Strength of Evidence of the Infectious Diseases Society of America Clinical Practice Guidelines | Q85193448 |
| | Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality | Q24530412 |
| | Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care | Q27860820 |
| | Epidemiology of invasive candidiasis: a persistent public health problem | Q29616758 |
| | Presentation of the PATH Alliance registry for prospective data collection and analysis of the epidemiology, therapy, and outcomes of invasive fungal infections | Q31130694 |
| | Epidemiology and predictors of mortality in cases of Candida bloodstream infection: results from population-based surveillance, barcelona, Spain, from 2002 to 2003. | Q33753405 |
| | Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis | Q34006585 |
| | Prior healthcare utilization as a predictor of survival for medical intensive care unit patients | Q34019253 |
| | Management of Candida species infections in critically ill patients | Q34280580 |
| | The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting | Q34509624 |
| | Anidulafungin versus fluconazole for invasive candidiasis | Q34580316 |
| | Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. | Q34936576 |
| | Anidulafungin compared with fluconazole in severely ill patients with candidemia and other forms of invasive candidiasis: support for the 2009 IDSA treatment guidelines for candidiasis | Q35908313 |
| | Invasive candidiasis in the intensive care unit | Q36408361 |
| | Attributable mortality of candidemia: a systematic review of matched cohort and case-control studies | Q36506378 |
| | Management of candidiasis in the intensive care unit | Q37026469 |
| | Determinants of mortality in non-neutropenic ICU patients with candidaemia | Q37360312 |
| | Variation in susceptibility of bloodstream isolates of Candida glabrata to fluconazole according to patient age and geographic location in the United States in 2001 to 2007. | Q37374850 |
| | Mechanism of increased fluconazole resistance in Candida glabrata during prophylaxis | Q37734345 |
| | Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials. | Q37993043 |
| | Use of peptide nucleic acid-fluorescence in situ hybridization for definitive, rapid identification of five common Candida species | Q42136599 |
| | Comparison of caspofungin and amphotericin B for invasive candidiasis | Q44255071 |
| | Attributable mortality of nosocomial candidemia, revisited | Q44386169 |
| | Current trends in the epidemiology of nosocomial bloodstream infections in patients with hematological malignancies and solid neoplasms in hospitals in the United States | Q44417864 |
| | Analysis of overall level of evidence behind Infectious Diseases Society of America practice guidelines | Q45041825 |
| | The utility of acute physiology and chronic health evaluation II scores for prediction of mortality among intensive care unit (ICU) and non-ICU patients with methicillin-resistant Staphylococcus aureus bacteremia | Q45746822 |
| | Candida bloodstream infections: comparison of species distribution and resistance to echinocandin and azole antifungal agents in Intensive Care Unit (ICU) and non-ICU settings in the SENTRY Antimicrobial Surveillance Program (2008-2009). | Q46306343 |
| | Candida bloodstream infections in intensive care units: analysis of the extended prevalence of infection in intensive care unit study | Q47583016 |
| | Adequacy of empirical antifungal therapy and effect on outcome among patients with invasive Candida species infections. | Q51185547 |
| | Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis. | Q51639404 |
| | Appropriate antibiotic therapy for ventilator-associated pneumonia and sepsis: a necessity, not an issue for debate. | Q51679092 |
| | Statistical validation of a severity of illness measure. | Q52433227 |
| | Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial | Q56970523 |
| | Systemic candidiasis in intensive care units: A multicenter, matched-cohort study | Q61649262 |
| | Time to Initiation of Fluconazole Therapy Impacts Mortality in Patients with Candidemia: A Multi‐Institutional Study | Q61833672 |
| P433 | issue | 1 | |
| P921 | main subject | candidemia | Q54946225 |
| P304 | page(s) | 37 | |
| P577 | publication date | 2013-10-30 | |
| P1433 | published in | BMC Anesthesiology | Q15754659 |
| P1476 | title | Candidemia in the critically ill: initial therapy and outcome in mechanically ventilated patients | |
| P478 | volume | 13 | |